We are excited to announce our strategic partnership with Cure Parkinson’s UK, working closely together to bring our research and clinical studies closer to patients and the public. We asked Helen Matthews, Deputy CEO of Cure Parkinson’s, to share with us her vision about the benefits of the research and clinical trials in Parkinson’s Disease,…
In 2011, Stefanie Studenski presented her data on the powerful prediction of slow gait speed as an independent risk factor for mortality. This landmark paper raised the awareness of almost all disciplines in medicine and allied healthcare professionals to measure gait speed and develop a different perspective on physical mobility. This paper is also part…
We are proud to announce that Mobilise-D will launch a webinar series, starting in February 2022! And we kick off with a bang, featuring a discussion about THE ALGORITHMS and Digital Mobility Outcomes (DMOs). Save the dates already now for all the webinars! We have designed the first series of five webinars, twice a month (February…
Walking has the potential to be a rich indicator of health in many medical conditions. In recent years, scientific research has proposed more than 100 digital mobility outcomes (DMOs) that could be used to assess walking, and thereby monitor health status, using digital technologies. Though they show great promise, these DMOs require further validation. Researchers must…
Novartis is now looking for a Digital Data Scientist to join their group and participate in their ground-breaking medical research activities that redefine the grammar for medicine in the post-genome era. The Digital Data Scientist in Novartis will understand complex and critical business problems, formulate integrated analytical approach to mine data sources, employ statistical methods…
Digital endpoints offer a great potential to be considered in the HTA framework. So far, however, there is no institutional way in. On February 15, 2021, IMI Neuronet hosted an online meeting of its working group on health technology assessment (HTA) and regulatory interactions, moderated by Diana O’Rourke from the National Institute for Health and Care Excellence (NICE). The discussions were based around the experiences of three different IMI projects that are…
The Digital Health Catalyst (DHC) was created by Mobilise-D and IDEA-FAST in response to the growing need for research and application in the area of real-world digital measurements. “The field will require a new generation of personnel from areas including clinical research and application, sensor and hardware development, infrastructure and data handling, data processing and…
From January 2021 onwards, Mobilise-D and IDEA-FAST, two ongoing EU Innovative Medicines Initiatives projects, will join forces to increase the impact and the benefits of digital health technologies developed by both projects.
Image by Christian Mueller/Shutterstock Innovative Medicines Initiative (IMI) just published a great “One step closer” article about the Mobilise-D Consortium. “Mobilise-D’s letter of support from the EMA is not only a nod to the promise of their research – it shows how important it is to connect with regulators early.” Read the full article here!
In the first year of Mobilise-D, we asked the European Medicines Agency (EMA) for qualification advice for Digital Mobility Outcomes (DMOs). EMA just published their letter of support that publicly endorses our initial stage in the wider objective of the Mobilise-D Consortium to pursue the qualification of Digital Mobility Outcomes (DMOs) as monitoring biomarkers of…